A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays

Antiviral Research

Volumn 82, Issue 1, 2009, Pages 12-21

  Roth, Jason P ^a   Li, Joseph K K ^a   Smee, Donald F ^a   Morrey, John D ^a   Barnard, Dale L ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

Antiviral assay; Enhanced green fluorescent protein; Human parainfluenza virus type 3; Recombinant virus

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL DESTRUCTION; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GENE INSERTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; VIRUS GENE; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; LUMINESCENT MEASUREMENTS; PARAINFLUENZA VIRUS 3, HUMAN; VIRUS REPLICATION;

HUMAN PARAINFLUENZA VIRUS 3; RNA VIRUSES;

EID: 62049083096     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.01.001     Document Type: Article

References (28)

1. Barnard D.L., Hubbard V.D., Burton J., Smee D.F., Morrey J.D., Otto M.J., and Sidwell R.W. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antiviral Chem. Chemother. 15 (2004) 15-22
2. Barnard D.L., Stowell V.D., Seley K.L., Hegde V.R., Das S.R., Rajappan V.P., Schneller S.W., Smee D.F., and Sidwell R.W. Inhibition of measles virus replication by 5′-nor carbocyclic adenosine analogues. Antiviral Chem. Chemother. 12 (2001) 241-250
3. Calain P., and Roux L. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA. J. Virol. 67 (1993) 4822-4830
4. Cattaneo R., Rebmann G., Schmid A., Baczko K., ter Meulen V., and Billeter M.A. Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J. 6 (1987) 681-688
5. Cavanaugh Jr. P.F., Moskwa P.S., Donish W.H., Pera P.J., Richardson D., and Andrese A.P. A semi-automated neutral red based chemosensitivity assay for drug screening. Invest. New Drugs 8 (1990) 347-354
6. De Clercq E. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv. Virus Res. 42 (1993) 1-55
7. Durbin A.P., Siew J.W., Murphy B.R., and Collins P.L. Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six. Virology 234 (1997) 74-83
8. Finter N.B. Dye uptake methods of assessing viral cytopathogenicity and their application to interferon assays. J. Gen. Virol. 5 (1969) 419-427
9. Fuerst T.R., Niles E.G., Studier F.W., and Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 8122-8126
10. Galinski M.S. Annotated nucleotide and protein sequences for selected paramyxoviridae. In: Kingsbury D.W. (Ed). The Paramyxoviruses (1991), Plenum Press, New York 537-568
11. Homann H.E., Hofschneider P.H., and Neubert W.J. Sendai virus gene expression in lytically and persistently infected cells. Virology 177 (1990) 131-140
12. Kraybill, B., 2005. http://iccb.med.harvard.edu/screening/Quantitative%20Assay%20Evaluation%20and%20Optimization%20complete%20(3).pdf.
13. Malakhov M.P., Aschenbrenner L.M., Smee D.F., Wandersee M.K., Sidwell R.W., Gubareva L.V., Mishin V.P., Hayden F.G., Kim D.H., Ing A., Campbell E.R., Yu M., and Fang F. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 50 (2006) 1470-1479
14. Mao H., Thakur C.S., Chattopadhyay S., Silverman R.H., Gudkov A., and Banerjee A.K. Inhibition of human parainfluenza virus type 3 infection by novel small molecules. Antiviral Res. 77 (2008) 83-94
15. Marschall M., Freitag M., Weiler S., Sorg G., and Stamminger T. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob. Agents Chemother. 44 (2000) 1588-1597
16. Matrosovich M., Matrosovich T., Garten W., and Klenk H.D. New low-viscosity overlay medium for viral plaque assays. Virol. J. 3 (2006) 63
17. Noah J.W., Severson W., Noah D.L., Rasmussen L., White E.L., and Jonsson C.B. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res. 73 (2007) 50-59
18. Ohsawa K., Yamada A., Takeuchi K., Watanabe Y., Miyata H., and Sato H. Genetic characterization of parainfluenza virus 3 derived from guinea pigs. J. Vet. Med. Sci. 60 (1998) 919-922
19. Perrotta A.T., and Been M.D. A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature 350 (1991) 434-436
20. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 (2001) 2002-2007
21. Sidwell R.W. Ribavirin: a review of antiviral efficacy. In: Pandalai G. (Ed). Recent Research and Development in Antimicrobial Agents and Chemotherapy (1996), Research Signpost, Kerala 219-256
22. Smee D.F., Morrison A.C., Barnard D.L., and Sidwell R.W. Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J. Virol. Methods 106 (2002) 71-79
23. Stokes A., Tierney E.L., Murphy B.R., and Hall S.L. The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain. Virus Res. 25 (1992) 91-103
24. Tapparel C., Maurice D., and Roux L. The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)3 is essential for replication. J. Virol. 72 (1998) 3117-3128
25. Towner J.S., Paragas J., Dover J.E., Gupta M., Goldsmith C.S., Huggins J.W., and Nichol S.T. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332 (2005) 20-27
26. Watanabe W., Konno K., Ijichi K., Inoue H., Yokota T., and Shigeta S. MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents. J. Virol. Methods 48 (1994) 257-265
27. Zhang J.H., Chung T.D., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
28. Zhang L., Bukreyev A., Thompson C.I., Watson B., Peeples M.E., Collins P.L., and Pickles R.J. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J. Virol. 79 (2005) 1113-1124